60 Degrees Pharmaceuticals (SXTP) Return on Capital Employed (2023 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Return on Capital Employed of 189.6% for Q1 2026, up 6331.0% year-over-year from 2.95% in Q1 2025, and down 2.27% quarter-over-quarter from 185.39% in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Return on Capital Employed (2023 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Return on Capital Employed for 4 consecutive years, with 189.6% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6331.0% year-over-year to 189.6%; the TTM figure through Mar 2026 stood at 189.6% (up 6331.0% YoY), while the FY2025 annual figure was 208.56%, down 1861.0% from the prior year.
- Return on Capital Employed slipped to 189.6% in Q1 2026 per SXTP's latest filing, from 185.39% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 68.34% in Q3 2023 and bottomed at 252.91% in Q1 2025.
- Historically, Return on Capital Employed has averaged 174.45% across 4 years, with a median of 189.6% in 2026.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 17342 bps — and 2026, when it soared 6331 bps.
- 60 Degrees Pharmaceuticals' Return on Capital Employed stood at 91.53% in 2023, then tumbled by 115 bps to 196.95% in 2024, then advanced by 6 bps to 185.39% in 2025, then slipped by 2 bps to 189.6% in 2026.
- Business Quant data shows SXTP's Return on Capital Employed at 189.6% in Q1 2026, 185.39% in Q4 2025, and 244.16% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -219.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -189.60% |
| Dec 31, 2025 | -185.39% |
| Sep 30, 2025 | -244.16% |
| Jun 30, 2025 | -227.19% |
| Mar 31, 2025 | -252.91% |
| Dec 31, 2024 | -196.95% |
| Sep 30, 2024 | -209.12% |
| Jun 30, 2024 | -174.27% |
| Mar 31, 2024 | -79.49% |
| Dec 31, 2023 | -91.53% |
| Sep 30, 2023 | -68.34% |